French drugmaker Sanofi plans to redeem a fast-track voucher to gain accelerated regulatory review of its experimental combination diabetes drug Lixilan, a once-daily injectable treatment that combines its blockbuster insulin Lantus with Lyxumia, a Type 2 diabetes medication currently marketed in Europe. Lyxumia is not yet approved in the United States but is currently under review by the Food and Drug Administration (FDA). It is in a class of type 2 diabetes drugs known as GLP 1 receptor agonists. Other drugs in this class include the brand names Byetta and Victoza. Sanofi hopes to give Lixilan the edge over competitor ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.